$ROIV News

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $36

Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum

TD Cowen Raises its Price Target on Roivant Sciences (ROIV)

TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $41

Roivant Sciences Ltd. 2025 Q4 - Results - Earnings Call Presentation

HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $34 Price Target

Roivant (ROIV) Climbs 15% on Swing to Profits

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

Roivant (ROIV) Q4 2025 Earnings Transcript

These Two Biotech Stocks Rocketed — And One Just Broke Out

Why These Two Biotech Stocks Just Rocketed, As One Prepares To Break Out

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?